ArticleInternational journal of women's health2026
Agreement Between the CerviCARE AI Artificial-Intelligence Software and Visual Inspection with Acetic Acid (VIA) for Cervical Cancer Screening in Women Aged Over 18 Years in Vinh Long Province, Vietnam: A Community-Based Cross-Sectional Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer is preventable, yet screening coverage remains low in low- and middle-income countries (LMICs), where HPV DNA testing and cytology are often unavailable and visual inspection with acetic acid (VIA) is the most widely used method. Artificial-intelligence (AI) image-analysis tools may support screening, so their agreement with VIA is of practical relevance. Objective: To describe cervical cancer screening results with CerviCARE AI, VIA, and Pap smear, and to evaluate the agreement between CerviCARE AI and VIA in women aged ≥18 years in Vinh Long Province, Vietnam, in 2025. Materials and Methods: A community-based cross-sectional study included 2757 women, of whom 2316 underwent all three methods. Agreement was assessed with Cohen's kappa (asymptotic and bootstrap 95% CIs), the exact McNemar test, and the prevalence-adjusted bias-adjusted kappa (PABAK). Results: Among 2316 women, CerviCARE AI classified 360 (15.5%) as abnormal, VIA was positive in 413 (17.8%), and and Pap smear was positive in only 4 (0.2%). CerviCARE AI and VIA showed 97.71% observed agreement and a Cohen's kappa of 0.918 (95% CI: 0.896-0.940; bootstrap 0.896-0.938), indicating almost perfect agreement, with a PABAK of 0.954. All 360 AI-abnormal cases were VIA-positive, whereas VIA flagged an additional 53 cases (exact McNemar p < 0.001), so AI-positive results were a subset of VIA. Agreement remained almost perfect across age strata (κ 0.83-1.00). In the overall questionnaire sample, only 2.6% of women had ever received HPV vaccination and 32.6% had ever been screened, although 98.0% considered screening necessary and 91.7% were willing to be vaccinated; cost was the most frequent barrier (49.0%). Conclusion: CerviCARE AI showed almost perfect agreement with VIA under community screening conditions and classified fewer cases as abnormal than VIA. These findings indicate feasibility and concordance rather than diagnostic accuracy and require validation against histopathology or HPV DNA testing before conclusions on diagnostic performance can be drawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.